Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07459660 · ClinicalTrials.gov registry record · Phase 2

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

A Phase 2 study, sponsored by MapLight Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
210
Enrollment target

NCT07459660: Recruiting Phase 2 study, sponsored by MapLight Therapeutics.

NCT07459660 is a Phase 2 study that is actively recruiting participants, run by MapLight Therapeutics. The registered enrollment target is 210 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (58% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07459660, a Phase 2 study, is actively recruiting participants, sponsored by MapLight Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
210 participants
Enrollment target

Study Summary

ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).

Interventions

  • DRUG ML-007C-MA

Trial Details

FieldValue
Enrollment Target 210 participants
Start Date 2026-03-25
Est. Completion 2029-03
Phase Phase 2
MapLight Therapeutics

5 total trials

What NCT07459660 shows while recruiting

NCT07459660 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (58% higher).

The record links to 0 conditions, and to 1 intervention - of which ML-007C-MA is the first listed.

NCT07459660 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07459660 about?

NCT07459660 is a clinical study titled "An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis". ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).

What is the current status of trial NCT07459660?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2026-03-25. Estimated completion is 2029-03.

What interventions are being tested in trial NCT07459660?

The interventions under investigation include: ML-007C-MA (DRUG).

Who is sponsoring clinical trial NCT07459660?

This trial is sponsored by MapLight Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07459660's enrollment target sits among peer trials

210 290th of 2000 higher than 1,707 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02665923 · 210 participants

    Gastric Emptying in Neonates and Infants After Formula Feeding

  • NCT03322891 · 210 participants · NA

    Improving Health Literacy in African-American Prostate Cancer Patients

  • NCT03544489 · 210 participants · Phase 2

    Effectiveness of Exercise After an ICD

  • NCT04408430 · 210 participants · NA

    The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07459660, the US trial registry maintained by the National Library of Medicine. NCT07459660 (mid enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.